Scientific Program
Presentations will be delivered virtually
Please find the agenda below.
*Agenda subject to change
Allied Healthcare Professional Agenda
| 8:00 AM – 8:15 AM | Welcome and Introductions |
| 8:15 AM – 9:00 AM | Primer on Immunology |
| 9:00 AM – 9:45 AM | Manage irAEs with novel immunotherapies |
| 9:45 AM – 10:00 AM | Practical Q&A and Panel Discussion |
| 10:00 AM – 10:15 AM | BREAK/VIRTUAL EXHIBITS |
| 10:15AM – 11:00 AM | Targeted agents in B-cell malignancies (New drugs, Mechanism of action, Toxicity) |
| 11:00 AM – 11:45 AM | Quality of life assessment and symptom management for AYA patients |
| 11:45 AM – 11:55 AM | Practical Q&A and Panel Discussion |
| 11:55 AM – 12:00 PM | Session Wrap-Up and Closing |
Friday: April 30, 2021
Presentation times are in CDT
| 1:00 PM – 1:15 PM | WELCOME AND INTRODUCTIONS |
| Mini Symposium on Indolent Lymphoma | |
| 1:00 PM – 1:15 PM | Pre-session ARS |
| 1:15 PM – 1:45 PM | Marginal Zone Lymphoma |
| 1:45 PM – 2:15 PM | Therapeutic Strategies in Newly Diagnosed Waldenstroms Macroglobulinemia |
| 2:15 PM – 2:30 PM | BREAK & VIRTUAL EXHIBITS |
| 2:30 PM – 3:00 PM | Beyond BTK and BCL2: What’s Next for CLL? |
| 3:00 PM – 3:15 PM | Post-session ARS, Panel Discussion and Q&A |
| 3:15 PM – 4:15 PM | Hematopathology Tumor Board |
| 4:15 PM – 4:30 PM | Post-session ARS, Panel Discussion and Q&A |
| 4:30 PM – 5:00 PM | General Session Wrap Up and Summary |
| 5:00 PM | Adjourn |
Saturday: May 1, 2021
Presentation times are in CDT
|
8:00 AM – 8:10 AM |
WELCOME AND INTRODUCTIONS |
| Mini Symposium on Aggressive Lymphomas | |
| 8:10 AM – 8:15 AM | Pre-session ARS |
| 8:00 AM – 8:20 AM | Treatment Approaches for Elderly Patients with DLBCL |
| 8:20 AM – 8:40 AM | Debate: CAR T-cell Therapy vs Chemotherapy + Autologous Transplant |
| 8:40 AM – 9:00 AM | Current Treatment Options for Relapsed/Refractory CTCL |
| 9:00 AM – 9:15 AM | Post-session ARS, Panel Discussion and Q&A |
| 9:15 AM – 9:45 AM | R/R MCL: The Emerging Landscape of Options |
| 9:45 AM – 10:00 AM | Post-session ARS, Panel Discussion and Q&A |
|
10:00 AM – 10:15AM |
BREAK & VIRTUAL EXHIBITS |
| Primary and Secondary CNS Lymphoma | |
| 10:15 AM – 10:20 AM | Pre-session ARS |
| 10:20 AM – 10:50 AM | Primary CNS Lymphoma |
| 10:50 AM – 11:20 AM | CNS Lymphoma Prophylaxis |
| 11:20 AM – 11:35 AM | Post-session ARS, Panel Discussion and Q&A |
| Mini Symposium on Targeted and Cellular Therapies | |
| 11:35 AM – 11:40 AM | Pre-session ARS |
| 11:40 AM – 12:00 PM | Predicting Efficacy and Toxicity with CAR T-cells |
| 12:00 PM – 12:20 PM | Bispecific Antibodies and How to Integrate Practice |
| 12:20 PM – 12:40 PM | Antibody-Drug Conjugates |
| 12:40 PM – 1:00 PM | Post-session ARS, Panel Discussion and Q&A |
|
1:00 PM – 1:30 PM |
LUNCH & VIRTUAL EXHIBITS |
| Mini Symposium on Imaging | |
| 1:30 PM – 1:35 PM | Pre-session ARS |
| 1:35 PM – 1:55 PM | Imaging in Lymphoma: From Gallium to Radiomics – What We Know Now |
| 1:55 PM – 2:15 PM | Interim Scans in Aggressive Lymphomas |
| 2:15 PM – 2:35 PM | New Imaging Techniques |
| 2:35 PM – 2:45 PM | Post-session ARS, Panel Discussion and Q&A |
| 2:45 PM – 3:05 PM | Impact of COVID-19 on Lymphoma Treatment |
| 3:05 PM – 3:15 PM | Q&A |
| 3:15 PM – 4:15 PM | Keynote: Next Steps in Follicular Lymphoma |
| 4:15 PM – 4:30 PM | Q&A |
| 4:30 PM – 4:50 PM | What Is the Best Second Line Treatment for Hodgkin Lymphoma? |
| 5:00 PM – 5:15 PM | Summary and Best of IUCLS |
| 5:15 PM | Adjourn |